Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer

Tekijä Sanne ten Hoorn, Cynthia Waasdorp, Martijn G. H. van Oijen, Helene Damhofer, Anne Trinh, Lan Zhao, Lisanne J. H. Smits, Sanne Bootsma, Gabi W. van Pelt, Wilma E. Mesker, Linda Mol, Kaitlyn K. H. Goey, Miriam Koopman, Jan Paul Medema, Jurriaan B. Tuynman, Inti Zlobec, Cornelis J. A. Punt, Louis Vermeulen, Maarten F. Bijlsma
Julkaistu 2022-04-01